Etiometry Achieves FDA Clearance for Cardiogenic Shock Automation Tool
Etiometry has secured FDA clearance for its Cardiogenic Shock Tool, the first automation solution for hospital-specific classification and tracking of cardiogenic shock. This development is crucial as timely identification can significantly impact patient outcomes in a condition associated with high mortality rates.
Theia Market Signal Identification - AI Assisted
Etiometry has received FDA clearance (K254066) for its Cardiogenic Shock Tool, which automates the classification and tracking of cardiogenic shock using data from physiologic monitoring. This tool aligns with SCAI guidelines and institutional protocols, aiming to reduce the documented cases of cardiogenic shock, which exceed 50% at advanced stages.
The platform enhances clinical decision-making, improves operational outcomes, and supports further care coordination. It offers real-time classification, longitudinal tracking of shock severity, and addresses significant challenges in timely intervention, documentation, and patient acuity measurement for performance and reimbursement. The impact of this tool on clinical efficacy and operational efficiency could reshape protocols for managing complex cardiac patients.
Comments